Advertisement

The Indian Journal of Pediatrics

, Volume 86, Issue 6, pp 515–519 | Cite as

Serum Sclerostin Level and Bone Mineral Density in Pediatric Hemophilic Arthropathy

  • Dalia M. E. El-MikkawyEmail author
  • Mohja A. Elbadawy
  • Shereen M. Abd El-Ghany
  • Dalia Samaha
Original Article

Abstract

Objective

To assess serum sclerostin levels in relation to severity of arthropathy and bone mineral density (BMD) in children with hemophilic arthropathy.

Methods

This cross-sectional study included 40 male children suffering from Hemophilia A, and 10 matched healthy controls. Assessment of factor VIII deficiency degree, frequency of bleeding, type of treatment, body mass index (BMI), disease severity using the Hemophilia Joint Health Score (HJHS) and lumbar spine (LS) Z score for bone mineral density (BMD) using dual-energy X-ray absorbiometry was done. Serum sclerostin levels were measured for all patients and controls.

Results

Significant difference of serum sclerostin levels between the patient and control groups with Mean ± SD (0.09 ± 0.07 ng/ml) and (0.04 ± 0.01 ng/ml) (P value = 0.028) respectively was found. Significant positive correlations between serum sclerostin levels and the patients’ age, and HJHS (P value <0.05) were found, while it had negative correlation with DEXA Z score, not reaching a significant value. LS-BMD-Z score levels ranged from (−4.5 to 1.2), with 15 patients with low BMD Z score (less than −2) representing 37.5% of total patients.

Conclusions

Serum sclerostin levels are elevated in hemophilic children denoting bone metabolism affection and correlates with increased age, and HJHS. Increased levels of serum sclerostin may identify hemophilic patients at high risk for developing osteoporosis.

Keywords

Sclerostin Hemophilia Arthropathy Bone mineral denisty 

Notes

Authors’ Contributions

DME El-M: Collection of patients from clinic, clinical assessment and HJHS assessment, prepare patients data for statistical analysis; MAE: Helped in clinical data assessment and writing the manuscript; SMA El-G: Collection of blood samples; DS: Laboratory analysis of serum sclerostin levels. DME El- M will act as guarantor for this paper.

Compliance with Ethical Standards

Conflict of Interest

None.

Source of Funding

None.

References

  1. 1.
    Hoyer LW. Hemophilia A. New Engl J Med. 1994;330:38–47.CrossRefGoogle Scholar
  2. 2.
    Gallacher SJ, Deighan C, Wallace AM, et al. Association of severe haemophilia A with osteoporosis: a densitometric and biochemical study. Q J Med. 1994;87:181–6.Google Scholar
  3. 3.
    Wallny TA, Scholz DT, Oldenburg J, et al. Osteoporosis in haemophilia–an underestimated co-morbidity? Haemophilia. 2007;13:79–84.CrossRefGoogle Scholar
  4. 4.
    Nair AP, Jijina F, Ghosh K, Madkaikar M, Shrikhande M, Nema M. Osteoporosis in young hemophiliacs from western India. Am J Hematol. 2007;82:453–7.CrossRefGoogle Scholar
  5. 5.
    Baron R, Rawadi G. Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148:2635–43.CrossRefGoogle Scholar
  6. 6.
    Krishnan V, Bryant HU, MacDougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116:1202–9.CrossRefGoogle Scholar
  7. 7.
    Van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004;199:805–14.CrossRefGoogle Scholar
  8. 8.
    Semënov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005;280:26770–5.CrossRefGoogle Scholar
  9. 9.
    Poole KE, van Bezooijen RL, Loveridge N. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005;19:1842–4.CrossRefGoogle Scholar
  10. 10.
    van Bezooijen RL, ten Dijke P, Papapoulos SE, Löwik CW. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev. 2005;16:319–27.CrossRefGoogle Scholar
  11. 11.
    Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;6:e25900.CrossRefGoogle Scholar
  12. 12.
    Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013;19:179–92.CrossRefGoogle Scholar
  13. 13.
    Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot–containing protein. Am J Hum Genet. 2001;68:577–89.CrossRefGoogle Scholar
  14. 14.
    Staehling-Hampton K, Proll S, Paeper BW, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet. 2002;110:144–52.CrossRefGoogle Scholar
  15. 15.
    Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24:578–88.CrossRefGoogle Scholar
  16. 16.
    Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19–26.CrossRefGoogle Scholar
  17. 17.
    El-Bakry S, Saber N, Zidan H, Samaha D. Sclerostin as an innovative insight towards understanding rheumatoid arthritis. Egypt Rheumatol. 2016;38:71–5.CrossRefGoogle Scholar
  18. 18.
    Visnjic D, Kalajzic Z, Rowe DW. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood. 2004;103:3258–64.CrossRefGoogle Scholar
  19. 19.
    Paschou SA, Anagnostis P, Karras S, et al. Bone mineral density in men and children with haemophilia a and B: A systematic review and meta-analysis. Osteoporos Int. 2014;25:2399–407.Google Scholar
  20. 20.
    Lewiecki EM, Gordon CM, Baim S, et al. International Society for Clinical Densitometry 2007 adult and pediatric official positions. Bone. 2008;43:1115–21.CrossRefGoogle Scholar
  21. 21.
    Bishop N, Braillon P, Burnham J, et al. Dual-energy X-ray absorptiometry assessment in children and adolescents with diseases that may affect the skeleton: the 2007 ISCD pediatric official positions. J Clin Densitom. 2008;11:29–42.CrossRefGoogle Scholar
  22. 22.
    Bachrach LK, Sills IN. Bone densitometry in children and adolescents. Pediatrics. 2011;127:189–94.CrossRefGoogle Scholar
  23. 23.
    Hilliard P, Funk S, Zourikian N, et al. Hemophilia joint health score reliability study. Hemophilia. 2006;12:518–25.CrossRefGoogle Scholar
  24. 24.
    Fewtrell MS. Bone densitometry in children assessed by dual x ray absorptiometry: uses and pitfalls. Arch Dis Child. 2003;88:795–8.CrossRefGoogle Scholar
  25. 25.
    Giordano P, Brunetti G, Lassandro G, et al. High serum sclerostin levels in children with haemophilia A. Br J Haematol. 2016;172:293–5.Google Scholar
  26. 26.
    Clarke BL, Drake MT. Clinical utility of serum sclerostin measurements. Bonekey Rep. 2013;2:361.CrossRefGoogle Scholar
  27. 27.
    Hassab HMA, El-Gendy WM, El-Noueam KI, Abd El Ghany HM, Elwan MMA. Serum cartilage oligomeric matrix protein reflects radiological damage and functional status in hemophilic arthropathy patients. Egypt Rheumatol. 2016;38:241–5.CrossRefGoogle Scholar
  28. 28.
    Barnes C, Wong P, Egan B, et al. Reduced bone density among children with severe hemophilia. Pediatrics. 2004;114:e177–81.CrossRefGoogle Scholar
  29. 29.
    Tlacuilo-Parra A, Morales-Zambrano R, Tostado-Rabago N, Esparza-Flores MA, Lopez-Guido B, Orozco-Alcala J. Inactivity is a risk factor for low bone mineral density among haemophilic children. Br J Haematol. 2008;140:562–7.CrossRefGoogle Scholar
  30. 30.
    EL Naeem RSA, El Hefnawy HEL, El Aziz OAA, El Mikkawy DMEED, Tantawy AAG, El-Ghany SMA. Assessment of bone mineral density and functional status in children with hemophilic arthropathy. Glob Adv Res J Med Med Sci. 2016;5:035–41.Google Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2019

Authors and Affiliations

  1. 1.Department of Physical Medicine, Rheumatology and Rehabilitation, Ain Shams University Hospitals, Faculty of MedicineAin Shams UniversityCairoEgypt
  2. 2.Department of Pediatrics, Ain Shams University Hospitals, Faculty of MedicineAin Shams UniversityCairoEgypt
  3. 3.Department of Clinical Pathology, Ain Shams University Hospitals, Faculty of MedicineAin Shams UniversityCairoEgypt

Personalised recommendations